6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
: O
* O
CNS B-OSE_Labeled_AE
depressant I-OSE_Labeled_AE
effects I-OSE_Labeled_AE
and O
daytime B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Abnormal B-OSE_Labeled_AE
thinking I-OSE_Labeled_AE
and O
behavioral B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Worsening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
Depression I-OSE_Labeled_AE
/ O
Suicidal B-OSE_Labeled_AE
ideation I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Sleep B-OSE_Labeled_AE
paralysis I-OSE_Labeled_AE
, O
hypnagogic B-OSE_Labeled_AE
/hypnopompic O
hallucinations I-OSE_Labeled_AE
, O
cataplexy B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
EXCERPT O
: O
The O
most O
common O
adverse O
reaction O
( O
reported O
in O
5 O
% O
or O
more O
of O
patients O
treated O
with O
BELSOMRA O
and O
at O
least O
twice O
the O
placebo O
rate O
) O
with O
BELSOMRA O
was O
somnolence O
( O
6.1 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Merck O
Sharp O
& O
Dohme O
Corp. O
, O
a O
subsidiary O
of O
Merck O
& O
Co. O
, O
Inc. O
, O
at O
1-877-888-4231 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

In O
3-month O
controlled O
efficacy O
trials O
( O
Study O
1 O
and O
Study O
2 O
) O
, O
1263 O
patients O
were O
exposed O
to O
BELSOMRA O
including O
493 O
patients O
who O
received O
BELSOMRA O
15 O
mg O
or O
20 O
mg O
( O
see O
Table O
1 O
) O
. O

In O
a O
long-term O
study O
, O
additional O
patients O
( O
n=521 O
) O
were O
treated O
with O
BELSOMRA O
at O
higher O
than O
recommended O
doses O
, O
including O
a O
total O
of O
160 O
patients O
who O
received O
BELSOMRA O
for O
at O
least O
one O
year O
. O

Table O
1 O
: O
Patient O
Exposure O
to O
BELSOMRA O
15 O
mg O
or O
20 O
mg O
in O
Study O
1 O
and O
Study O
2 O
Patients O
Treated O
BELSOMRA15 O
mg O
BELSOMRA20 O
mg O
For O
> O
= O
1 O
Day O
( O
n O
) O
202 O
291 O
Men O
( O
n O
) O
69 O
105 O
Women O
( O
n O
) O
133 O
186 O
Mean O
Age O
( O
years O
) O
70 O
45 O
For O
> O
= O
3 O
Months O
( O
n O
) O
118 O
172 O
The O
pooled O
safety O
data O
described O
below O
( O
see O
Table O
2 O
) O
reflect O
the O
adverse O
reaction O
profile O
during O
the O
first O
3 O
months O
of O
treatment O
. O

Adverse O
Reactions O
Resulting O
in O
Discontinuation O
of O
Treatment O
The O
incidence O
of O
discontinuation O
due O
to O
adverse O
reactions O
for O
patients O
treated O
with O
15 O
mg O
or O
20 O
mg O
of O
BELSOMRA O
was O
3 O
% O
compared O
to O
5 O
% O
for O
placebo O
. O

No O
individual O
adverse O
reaction O
led O
to O
discontinuation O
at O
an O
incidence O
> O
=1 O
% O
. O

Most O
Common O
Adverse O
Reactions O
In O
clinical O
trials O
of O
patients O
with O
insomnia B-Not_AE_Candidate
treated O
with O
BELSOMRA O
15 O
mg O
or O
20 O
mg O
, O
the O
most O
common O
adverse O
reaction O
( O
reported O
in O
5 O
% O
or O
more O
of O
patients O
treated O
with O
BELSOMRA O
and O
at O
least O
twice O
the O
placebo O
rate O
) O
was O
somnolence B-OSE_Labeled_AE
( O
BELSOMRA O
7 O
% O
; O
placebo O
3 O
% O
) O
. O

Table O
2 O
shows O
the O
percentage O
of O
patients O
with O
adverse O
reactions O
during O
the O
first O
three O
months O
of O
treatment O
, O
based O
on O
the O
pooled O
data O
from O
3-month O
controlled O
efficacy O
trials O
( O
Study O
1 O
and O
Study O
2 O
) O
. O

At O
doses O
of O
15 O
or O
20 O
mg O
, O
the O
incidence O
of O
somnolence B-OSE_Labeled_AE
was O
higher O
in O
females O
( O
8 O
% O
) O
than O
in O
males O
( O
3 O
% O
) O
. O

Of O
the O
adverse O
reactions O
reported O
in O
Table O
2 O
, O
the O
following O
occurred O
in O
women O
at O
an O
incidence O
of O
at O
least O
twice O
that O
in O
men O
: O
headache B-OSE_Labeled_AE
, O
abnormal B-OSE_Labeled_AE
dreams I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
, O
and O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
. O

The O
adverse O
reaction O
profile O
in O
elderly O
patients O
was O
generally O
consistent O
with O
non-elderly O
patients O
. O

The O
adverse O
reactions O
reported O
during O
long-term O
treatment O
up O
to O
1 O
year O
were O
generally O
consistent O
with O
those O
observed O
during O
the O
first O
3 O
months O
of O
treatment O
. O

Table O
2 O
: O
Percentage O
of O
Patients O
with O
Adverse O
Reactions O
Incidence O
> O
=2 O
% O
and O
Greater O
than O
Placebo O
in O
3-Month O
Controlled O
Efficacy O
Trials O
( O
Study O
1 O
and O
Study O
2 O
) O
Placebo O
BELSOMRA O
( O
20 O
mg O
in O
non-elderly O
or O
15 O
mg O
in O
elderly O
patients O
) O
n=767 O
n=493 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
1 O
2 O
Dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
1 O
2 O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
1 O
2 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
6 O
7 O
Somnolence B-OSE_Labeled_AE
3 O
7 O
Dizziness B-OSE_Labeled_AE
2 O
3 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Abnormal B-OSE_Labeled_AE
dreams I-OSE_Labeled_AE
1 O
2 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
1 O
2 O
Dose O
Relationship O
for O
Adverse O
Reactions O
There O
is O
evidence O
of O
a O
dose O
relationship O
for O
many O
of O
the O
adverse O
reactions O
associated O
with O
BELSOMRA O
use O
, O
particularly O
for O
certain O
CNS B-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
. O

In O
a O
placebo-controlled O
crossover O
study O
( O
Study O
3 O
) O
, O
non-elderly O
adult O
patients O
were O
treated O
for O
up O
to O
one O
month O
with O
BELSOMRA O
at O
doses O
of O
10 O
mg O
, O
20 O
mg O
, O
40 O
mg O
( O
2 O
times O
the O
maximum O
recommended O
dose O
) O
or O
80 O
mg O
( O
4 O
times O
the O
maximum O
recommended O
dose O
) O
. O

In O
patients O
treated O
with O
BELSOMRA O
10 O
mg O
( O
n=62 O
) O
, O
although O
no O
adverse O
reactions O
were O
reported O
at O
an O
incidence O
of O
> O
=2 O
% O
, O
the O
types O
of O
adverse O
reactions O
observed O
were O
similar O
to O
those O
observed O
in O
patients O
treated O
with O
BELSOMRA O
20 O
mg O
. O
BELSOMRA O
was O
associated O
with O
a O
dose-related O
increase O
in O
somnolence B-OSE_Labeled_AE
: O
2 O
% O
at O
the O
10 O
mg O
dose O
, O
5 O
% O
at O
the O
20 O
mg O
dose O
, O
12 O
% O
at O
the O
40 O
mg O
dose O
, O
and O
11 O
% O
at O
the O
80 O
mg O
dose O
, O
compared O
to O
< O
1 O
% O
for O
placebo O
. O

BELSOMRA O
was O
also O
associated O
with O
a O
dose-related O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
: O
1 O
mg/dL O
at O
the O
10 O
mg O
dose O
, O
2 O
mg/dL O
at O
the O
20 O
mg O
dose O
, O
3 O
mg/dL O
at O
the O
40 O
mg O
dose O
, O
and O
6 O
mg/dL O
at O
the O
80 O
mg O
dose O
after O
4 O
weeks O
of O
treatment O
, O
compared O
to O
a O
4 O
mg/dL O
decrease O
for O
placebo O
. O

